CytomX Therapeutics will report Q2 financial results on August 6, 2026, followed by a conference call and webcast.
Quiver AI Summary
CytomX Therapeutics, Inc. announced that it will release its second quarter financial results on August 6, 2026, after U.S. market close, followed by a conference call and webcast at 5:00 p.m. ET. The company focuses on developing innovative, conditionally activated cancer therapies through its proprietary PROBODY® platform. CytomX's pipeline includes Varsetatug masetecan, a targeted antibody-drug conjugate for metastatic colorectal cancer, and CX-801, a masked cytokine being developed for metastatic melanoma. The company aims to create safer, more effective oncological treatments and has established collaborations with major industry players like Amgen, Regeneron, and Moderna. More information can be found on their website.
Potential Positives
- CytomX Therapeutics will report its second quarter financial results, which could provide insights into the company’s financial health and progress, potentially affecting investor confidence.
- The scheduled conference call and webcast allows for direct communication with stakeholders, enhancing transparency and engagement with investors.
- CytomX's innovative PROBODY® therapeutic platform and its focus on localized cancer treatments position the company as a leader in a niche area of oncology, highlighting its commitment to developing safer therapies.
- The collaboration with established leaders in oncology like Amgen, Regeneron, and Moderna strengthens CytomX's strategic positioning and could enhance its credibility and resource access in the market.
Potential Negatives
- The press release does not provide any specific financial forecasts or information about the company's second quarter financial results, which may lead to concerns about transparency or performance if results are anticipated to be poor.
- There is no mention of any recent achievements or advancements in their clinical pipeline, which could indicate stagnation or lack of progress in their development efforts.
- The absence of information regarding regulatory approvals or partnerships in the release may raise questions about the company's strategic direction and competitive position in the market.
FAQ
When will CytomX report its second quarter financial results?
CytomX will report its second quarter financial results on August 6, 2026, after U.S. markets close.
How can I access CytomX's conference call?
You can access the live conference call by visiting CytomX’s Events and Presentations page on their website.
What is the focus of CytomX Therapeutics?
CytomX is focused on developing novel conditionally activated, masked PROBODY® therapeutics for cancer treatment.
What are the key candidates in CytomX's pipeline?
Key candidates include varsetatug masetecan (Varseta-M) for metastatic colorectal cancer and CX-801 for metastatic melanoma.
Who can I contact for more information about CytomX?
You can contact Chris Ogden, SVP and Chief Financial Officer, at [email protected] for more details.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CTMX Insider Trading Activity
$CTMX insiders have traded $CTMX stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $CTMX stock by insiders over the last 6 months:
- SEAN A. MCCARTHY (CEO) sold 118,969 shares for an estimated $764,137
- MARCIA BELVIN (SVP, Chief Scientific Officer) sold 31,492 shares for an estimated $202,273
- YU-WAYE CHU (Chief Medical Officer) sold 21,279 shares for an estimated $136,675
- CHRISTOPHER OGDEN (Chief Financial Officer) has made 0 purchases and 2 sales selling 20,947 shares for an estimated $129,064.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CTMX Hedge Fund Activity
We have seen 125 institutional investors add shares of $CTMX stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 9,326,480 shares (+1064.3%) to their portfolio in Q1 2026, for an estimated $43,834,456
- COMMODORE CAPITAL LP removed 7,692,300 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $36,153,810
- FMR LLC added 7,267,528 shares (+29.4%) to their portfolio in Q1 2026, for an estimated $34,157,381
- KYNAM CAPITAL MANAGEMENT, LP added 6,047,016 shares (+67.4%) to their portfolio in Q1 2026, for an estimated $28,420,975
- CITADEL ADVISORS LLC added 5,063,889 shares (+1479.4%) to their portfolio in Q1 2026, for an estimated $23,800,278
- NEXTECH INVEST, LTD. added 4,449,932 shares (+inf%) to their portfolio in Q1 2026, for an estimated $20,914,680
- ELMIND CAPITAL, LP added 3,850,000 shares (+550.0%) to their portfolio in Q1 2026, for an estimated $18,095,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CTMX Analyst Ratings
Wall Street analysts have issued reports on $CTMX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 03/18/2026
To track analyst ratings and price targets for $CTMX, check out Quiver Quantitative's $CTMX forecast page.
$CTMX Price Targets
Multiple analysts have issued price targets for $CTMX recently. We have seen 8 analysts offer price targets for $CTMX in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $11.0 on 05/11/2026
- Joseph Catanzaro from Piper Sandler set a target price of $12.0 on 03/23/2026
- Etzer Darout from Barclays set a target price of $16.0 on 03/19/2026
- Michael Schmidt from Guggenheim set a target price of $15.0 on 03/18/2026
- Roger Song from Jefferies set a target price of $16.0 on 03/18/2026
- Robert Driscoll from Wedbush set a target price of $11.0 on 03/17/2026
- Anupam Rama from JP Morgan set a target price of $12.0 on 03/16/2026
Full Release
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report second quarter financial results on Thursday, August 6, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations . Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY
®
therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY
®
cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit
www.cytomx.com
and follow us on
LinkedIn
and
X
(formerly Twitter)
.
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
[email protected]
Investor Contact:
Precision AQ
Stephanie Ascher
[email protected]
Media Contact:
Precision AQ
Colleen Ketchum
[email protected]
